Prognosis of CDKN2A germline mutation in patients with familial melanoma: a systematic review and meta-analysis
- Taibo, Ana 2
- Paradela, Sabela 2
- Suanzes-Hernández, Jorge 1
- Balboa-Barreiro, Vanesa 1
- Amado-Bouza, Javier 1
- Fonseca, Eduardo 2
- 1 Research Support Unit, University Hospital of A Coruña, Instituto de Investigación Biomédica de A Coruña (INIBIC), Spain
- 2 Department of Dermatology, University Hospital of A Coruña
ISSN: 0960-8931
Ano de publicación: 2023
Tipo: Artigo
Outras publicacións en: Melanoma Research
Resumo
Familial melanoma is defined as melanoma occurring in two or more first-degree relatives by the WHO. Germline mutations are isolated in a subset of them. It is well known that CDKN2A is the most frequently mutated high-risk gene in familial melanoma, however, the prognosis it confers to patients who carry its mutations is still controversial. This review aims to assess whether germline mutations imply a worse prognosis in patients with familial melanoma. A systematic review and meta-analysis were conducted by searching the electronic databases PubMed/MEDLINE, EMBASE, and Cochrane Library. Data from 3 independent populations were eventually included in the meta-analysis, involving 291 cases and 57 416 controls. The results of this systematic review and meta-analysis suggest that there is a tendency for patients with germline mutations in the CDKN2A gene to have a worse overall survival (HR = 1.30, 95% CI = 0.99-1.69, P = 0.05) and melanoma-specific survival (HR = 1.5, 95% CI = 0.97-2.31, P = 0.07). Carrier patients would not only have more incidence of melanoma and a higher risk of a second melanoma, but they also seem to have a worse prognosis. The inclusion of gene panel testing in clinical practice and the collaboration within consortia are needed to provide further evidence on the prognosis of these patients.
Referencias bibliográficas
- Puig, (2016), Genet Med, 18, pp. 727, 10.1038/gim.2015.160
- Helgadottir, (2016), J Natl Cancer Inst, 108, pp. 1, 10.1093/jnci/djw135
- Helgadottir, (2017), J Am Acad Dermatol, 77, pp. 893, 10.1016/j.jaad.2017.05.050
- Ipenburg, (2022), J Am Acad Dermatol, 87, pp. 479, 10.1016/j.jaad.2021.10.024
- Dalmasso, (2019), J Am Acad Dermatol, 80, pp. 1263, 10.1016/j.jaad.2018.07.060
- Tierney, (2007), Trials, 8, pp. 16, 10.1186/1745-6215-8-16
- DerSimonian, (1986), Control Clin Trials, 7, pp. 177, 10.1016/0197-2456(86)90046-2
- Balduzzi, (2019), Evid Based Ment Health, 22, pp. 153, 10.1136/ebmental-2019-300117
- Toussi, (2020), J Cutan Pathol, 47, pp. 606, 10.1111/cup.13689
- Van der Velden, (2001), Am J Hum Genet, 69, pp. 774, 10.1086/323411
- Potrony, (2014), J Am Acad Dermatol, 71, pp. 888, 10.1016/j.jaad.2014.06.036
- Helgadottir, (2020), J Med Genet, 57, pp. 316, 10.1136/jmedgenet-2018-105610
- Robles-Espinoza, (2014), Nat Genet, 46, pp. 478, 10.1038/ng.2947
- Potrony, (2019), Br J Dermatol, 181, pp. 105, 10.1111/bjd.17443
- Zauderer, (2019), J Thorac Oncol, 14, pp. 1989, 10.1016/j.jtho.2019.07.002
- Ewens, (2018), BMC Cancer, 18, pp. 1172, 10.1186/s12885-018-5079-x
- Davies, (2012), Pigment Cell Melanoma Res, 25, pp. 384, 10.1111/j.1755-148X.2012.00982.x
- Hatvani, (2014), Exp Dermatol, 23, pp. 361, 10.1111/exd.12382
- Davies, (2014), Int J Cancer, 135, pp. 1625, 10.1002/ijc.28796
- Yuan, (2015), Int J Cancer, 137, pp. 638, 10.1002/ijc.29429
- de With, (2021), Cancers, 13, pp. 1370, 10.3390/cancers13061370
- Amaral, (2020), Cancers, 12, pp. 1101, 10.3390/cancers12051101
- Mucci, (2016), JAMA, 315, pp. 68, 10.1001/jama.2015.17703
- Campos, (2020), Genes (Basel), 11, pp. 403, 10.3390/genes11040403
- Duffy, (2018), Nat Commun, 9, pp. 4774, 10.1038/s41467-018-06649-5
- Pastorino, (2020), Cancers (Basel), 12, pp. 1007, 10.3390/cancers12041007
- Hampel, (2015), Genet Med, 17, pp. 70, 10.1038/gim.2014.147
- Bruno, (2022), ESMO Open, 7, pp. 100525, 10.1016/j.esmoop.2022.100525
- Taylor, (2019), J Am Acad Dermatol, 81, pp. 386, 10.1016/j.jaad.2019.01.079